0001694665-23-000160.txt : 20230929
0001694665-23-000160.hdr.sgml : 20230929
20230929160217
ACCESSION NUMBER: 0001694665-23-000160
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230927
FILED AS OF DATE: 20230929
DATE AS OF CHANGE: 20230929
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GILL SIMBA
CENTRAL INDEX KEY: 0001180763
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38473
FILM NUMBER: 231295359
MAIL ADDRESS:
STREET 1: 515 GALVESTON DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evelo Biosciences, Inc.
CENTRAL INDEX KEY: 0001694665
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 465594527
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE, 600/700, SUITE 7-201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-577-0300
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE, 600/700, SUITE 7-201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wk-form4_1696017728.xml
FORM 4
X0508
4
2023-09-27
0
0001694665
Evelo Biosciences, Inc.
EVLO
0001180763
GILL SIMBA
C/O EVELO BIOSCIENCES, INC.
ONE KENDALL SQUARE, 600/700, SUITE 7-201
CAMBRIDGE
MA
02139
1
1
0
0
President & CEO
1
Common Stock
2023-09-27
4
M
0
15000
A
18754
D
Common Stock
2023-09-28
4
S
0
1996
3.94
D
16758
D
Restricted Stock Units
2023-09-27
4
A
0
60000
0
A
Common Stock
60000
60000
D
Restricted Stock Units
2023-09-27
4
M
0
15000
0
D
Common Stock
15000
45000
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person on December 7, 2022, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $3.92 to $3.94, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
The RSUs vested as to 25% of the underlying shares on the grant date of September 27, 2023, with the remaining shares vesting in twelve (12) equal quarterly installments such that all of the RSUs will become vested on the third anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date.
/s/ Marella Thorell, Attorney-in-Fact for Balkrishan (Simba) Gill, Ph.D.
2023-09-29